Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults

被引:0
|
作者
Shin, Thomas [1 ]
Wells, Chad R. [2 ]
Shoukat, Affan [3 ]
Potter-Schwartz, Lilia [2 ]
Langevin, Edith [4 ]
Langley, Joanne M. [5 ]
Galvani, Alison P. [2 ]
Moghadas, Seyed M. [6 ]
机构
[1] Sanofi, Hlth Econ & Outcomes Res, Bridgewater, NJ USA
[2] Yale Sch Publ Hlth, Ctr Infect Dis Modeling & Anal, New Haven, CT USA
[3] Univ Regina, Dept Math & Stat, Regina, SK, Canada
[4] Sanofi, Hlth Econ Value Assessment, Lyon, France
[5] Dalhousie Univ, Canadian Ctr Vaccinol, Halifax, NS, Canada
[6] York Univ, Agent Based Modelling Lab, 4700 Keele St, Toronto, ON M3J 1P3, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
AGED; 13-17; YEARS; UNITED-STATES; EPIDEMIOLOGY; PREVENTION; COVERAGE;
D O I
10.1001/jamanetworkopen.2024.43551
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance Beginning in 2005, the US implemented routine immunization of adolescents with a quadrivalent conjugate vaccine (MenACWY) for the prevention of invasive meningococcal disease (IMD). Objectives To assess whether MenACWY immunization was associated with a reduced IMD burden among the US adolescent population and how the downward trajectory of IMD that began in the mid-1990s might have evolved in the absence of vaccination efforts. Design, Setting, and Participants In this decision analytical study, a bayesian hierarchical Poisson regression model was developed to investigate the potential trajectory of IMD among US adolescents and young adults without vaccination and evaluate the direct association of vaccination with IMD burden. The model included the entire age-stratified US population and was fitted to national incidence data for serogroups C, W, and Y from January 1, 2001, to December 31, 2021, with stratification by vaccination status for IMD cases. Intervention Simulated counterfactual scenario of absent vaccination from 2005 to 2021, while retaining the incidence rate of IMD for unvaccinated individuals estimated during model fitting. Main Outcomes and Measures The main outcomes were the estimated numbers of IMD cases and deaths averted by MenACWY vaccination among US adolescents and young adults aged 11 to 23 years. Results Among the entire US population from 2005 to 2021, MenACWY vaccination prevented an estimated 172 (95% credible interval [CrI], 85-345) cases of IMD among US adolescents 11 to 15 years of age and 328 (95% CrI, 164-646) cases of IMD among those aged 16 to 23 years. Absent vaccination, the cumulative incidence of IMD in these age groups would have been at least 59% higher than reported over the same period with vaccination. Using case fatality rates of unvaccinated individuals derived from national data, vaccination averted an estimated 16 (95% CrI, 8-31) deaths among adolescents aged 11 to 15 years and 38 (95% CrI, 19-75) deaths among those aged 16 to 23 years. Conclusions and Relevance This decision analytical model suggests that the MenACWY vaccination program in the US was associated with a reduced burden of meningococcal disease. Without vaccination, the incidence rates per 100 000 adolescents and young adults would have been substantially higher than those observed during the vaccine era.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults
    Bertolini, Daniela Vinhas
    Costa, Luciana Scarlazzari
    van der Heijden, Inneke Marie
    Sato, Helena Keiko
    de Sousa Marques, Heloisa Helena
    VACCINE, 2012, 30 (37) : 5482 - 5486
  • [22] Immunogenicity and Safety of Concomitant Administration of a Combined Hepatitis A/ B Vaccine and a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults
    Alberer, Martin
    Burchard, Gerd
    Jelinek, Tomas
    Reisinger, Emil C.
    Meyer, Seetha
    Forleo-Neto, Eduardo
    Dagnew, Alemnew F.
    Arora, Ashwani Kumar
    JOURNAL OF TRAVEL MEDICINE, 2015, 22 (02) : 105 - 114
  • [23] Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
    Sow, Samba O. O.
    Tapia, Milagritos D. D.
    Haidara, Fadima Cheick
    Diallo, Fatoumata
    Traore, Youssouf
    Traore, Awa
    Kodio, Mamoudou
    Borrow, Ray
    Townsend-Payne, Kelly
    Yuan, Lin
    Yang, Shuyuan
    Shi, Lei
    Chen, Jingjing
    Fang, Guoliang
    Lin, Jianxiang
    Hu, Ruoyu
    Viviani, Simonetta
    Huang, Zhen
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [24] ROLE OF VIDEO VERSUS TEXT INFORMATION IN WILLINGNESS TO BE VACCINATED FOR INVASIVE MENINGOCOCCAL DISEASE AMONG US ADOLESCENTS/YOUNG ADULTS AND PARENTS
    Schley, K.
    Whichello, C.
    Hauber, B.
    Krucien, N.
    Cappelleri, J. C.
    Peyrani, P.
    Presa, J.
    Coulter, J.
    Heidenreich, S.
    VALUE IN HEALTH, 2024, 27 (06) : S296 - S296
  • [25] Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure
    Wang, Xin
    Shutt, Kathleen A.
    Vuong, Jeni T.
    Cohn, Amanda
    MacNeil, Jessica
    Schmink, Susanna
    Plikaytis, Brian
    Messonnier, Nancy E.
    Harrison, Lee H.
    Clark, Thomas A.
    Mayer, Leonard W.
    JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (12): : 1887 - 1894
  • [26] Immune Persistence, Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster Dose in Adolescents and Adults Vaccinated Against Meningococcal Disease 3-6 Years Earlier
    Dhingra, Mandeep Singh S.
    Peterson, James
    Deseda, Carmen
    Julien, Katie
    Zambrano, Betzana
    Anez, German
    Shi, Jiayuan
    Pan, Judy
    Arroum, Habiba
    Varghese, Kucku
    Jordanov, Emilia
    PEDIATRICS, 2022, 149 (01)
  • [27] Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra
    Reisinger, Keith S.
    Baxter, Roger
    Block, Stanley L.
    Shah, Jina
    Bedell, Lisa
    Dull, Peter M.
    CLINICAL AND VACCINE IMMUNOLOGY, 2009, 16 (12) : 1810 - 1815
  • [28] Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease
    Hedari, Carine P.
    Khinkarly, Rima W.
    Dbaibo, Ghassan S.
    INFECTION AND DRUG RESISTANCE, 2014, 7 : 85 - 99
  • [29] Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naive and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study
    van der Vliet, D.
    Vesikari, T.
    Sandner, B.
    Martinon-Torres, F.
    Muzsay, G.
    Forsten, A.
    Adelt, T.
    Diaz Gonzalez, C.
    Simko, R.
    B'Chir, S.
    Neveu, D.
    Jordanov, E.
    Dhingra, M. S.
    EPIDEMIOLOGY AND INFECTION, 2021, 149
  • [30] Safety of Quadrivalent Meningococcal Conjugate Vaccine in Children 2-10 Years
    Tartof, Sara Yee
    Sy, Lina S.
    Ackerson, Bradley K.
    Hechter, Rulin C.
    Haag, Mendel
    Slezak, Jeffrey M.
    Luo, Yi
    Fischetti, Christine A.
    Takhar, Harp S.
    Miao, Yan
    Solano, Zendi
    Jacobsen, Steven J.
    Tseng, Hung-Fu
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (11) : 1087 - 1092